CR20250069A - Formas cristalinas y sales de un agonista del receptor muscarínico - Google Patents
Formas cristalinas y sales de un agonista del receptor muscarínicoInfo
- Publication number
- CR20250069A CR20250069A CR20250069A CR20250069A CR20250069A CR 20250069 A CR20250069 A CR 20250069A CR 20250069 A CR20250069 A CR 20250069A CR 20250069 A CR20250069 A CR 20250069A CR 20250069 A CR20250069 A CR 20250069A
- Authority
- CR
- Costa Rica
- Prior art keywords
- salts
- crystalline forms
- muscarinic receptor
- receptor agonist
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta invención se refiere a compuestos y sales de los mismos que son agonistas de los receptores muscarínicos y que son útiles en el tratamiento de enfermedades mediadas por receptores muscarínicos. También se proporcionan formas cristalinas de los compuestos y sales de los mismos; composiciones farmacéuticas que contengan sus compuestos y sales, o formas cristalinas de los mismos; usos terapéuticos de los compuestos y sales de los mismos, o de sus formas cristalinas; métodos de síntesis de los mismos; e intermedios útiles en dichos métodos de síntesis.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2211399.7A GB202211399D0 (en) | 2022-08-04 | 2022-08-04 | Muscarinic receptor agonists |
| GBGB2305444.8A GB202305444D0 (en) | 2023-04-13 | 2023-04-13 | Muscarinic receptor agonists |
| GBGB2309615.9A GB202309615D0 (en) | 2023-06-26 | 2023-06-26 | Muscarinic receptor agonists |
| PCT/EP2023/071591 WO2024028458A2 (en) | 2022-08-04 | 2023-08-03 | Muscarinic receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20250069A true CR20250069A (es) | 2025-05-26 |
Family
ID=87696205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20250069A CR20250069A (es) | 2022-08-04 | 2023-08-03 | Formas cristalinas y sales de un agonista del receptor muscarínico |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20250340531A1 (es) |
| EP (2) | EP4508045B1 (es) |
| JP (1) | JP2025526601A (es) |
| KR (1) | KR20250041066A (es) |
| CN (1) | CN119866336A (es) |
| AR (1) | AR130114A1 (es) |
| AU (1) | AU2023317835A1 (es) |
| CA (1) | CA3263797A1 (es) |
| CL (1) | CL2025000299A1 (es) |
| CO (1) | CO2025002413A2 (es) |
| CR (1) | CR20250069A (es) |
| DK (1) | DK4508045T3 (es) |
| DO (1) | DOP2025000015A (es) |
| ES (1) | ES3050097T3 (es) |
| FI (1) | FI4508045T3 (es) |
| HR (1) | HRP20251427T1 (es) |
| IL (1) | IL318739A (es) |
| JO (1) | JOP20250025A1 (es) |
| LT (1) | LT4508045T (es) |
| MA (1) | MA69856B1 (es) |
| MD (1) | MD4508045T2 (es) |
| MX (1) | MX2025001312A (es) |
| PE (1) | PE20251236A1 (es) |
| PL (1) | PL4508045T3 (es) |
| PT (1) | PT4508045T (es) |
| RS (1) | RS67422B1 (es) |
| SI (1) | SI4508045T1 (es) |
| TW (1) | TW202416955A (es) |
| WO (1) | WO2024028458A2 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025030095A1 (en) * | 2023-08-03 | 2025-02-06 | Neurocrine Biosciences, Inc. | Methods of synthesis |
| WO2026050229A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Method of treating a neurological or psychiatric disease or disorder |
| WO2026050231A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Method of treating a bipolar disorder |
| WO2026050236A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder |
| WO2026050225A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Method of treating a neurological or psychiatric disease or disorder |
| WO2026050238A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Muscarinic receptor agonist for use in the treatment of a neurological or psychiatric disorder |
| WO2026050278A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Solid oral pharmaceutical formulations comprising a muscarinic receptor agonist |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201500499TA (en) * | 2012-08-10 | 2015-03-30 | Boehringer Ingelheim Int | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
| SG11201606269WA (en) | 2014-02-06 | 2016-09-29 | Heptares Therapeutics Ltd | Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists |
-
2023
- 2023-08-03 TW TW112129182A patent/TW202416955A/zh unknown
- 2023-08-03 PL PL23757194.8T patent/PL4508045T3/pl unknown
- 2023-08-03 FI FIEP23757194.8T patent/FI4508045T3/fi active
- 2023-08-03 MD MDE20250179T patent/MD4508045T2/ro unknown
- 2023-08-03 LT LTEPPCT/EP2023/071591T patent/LT4508045T/lt unknown
- 2023-08-03 PT PT237571948T patent/PT4508045T/pt unknown
- 2023-08-03 KR KR1020257006895A patent/KR20250041066A/ko active Pending
- 2023-08-03 SI SI202330050T patent/SI4508045T1/sl unknown
- 2023-08-03 RS RS20251164A patent/RS67422B1/sr unknown
- 2023-08-03 US US18/867,575 patent/US20250340531A1/en active Pending
- 2023-08-03 EP EP23757194.8A patent/EP4508045B1/en active Active
- 2023-08-03 AR ARP230102050A patent/AR130114A1/es unknown
- 2023-08-03 CR CR20250069A patent/CR20250069A/es unknown
- 2023-08-03 ES ES23757194T patent/ES3050097T3/es active Active
- 2023-08-03 PE PE2025000295A patent/PE20251236A1/es unknown
- 2023-08-03 MA MA69856A patent/MA69856B1/fr unknown
- 2023-08-03 AU AU2023317835A patent/AU2023317835A1/en active Pending
- 2023-08-03 CA CA3263797A patent/CA3263797A1/en active Pending
- 2023-08-03 EP EP25198643.6A patent/EP4663190A3/en active Pending
- 2023-08-03 WO PCT/EP2023/071591 patent/WO2024028458A2/en not_active Ceased
- 2023-08-03 JP JP2025505853A patent/JP2025526601A/ja active Pending
- 2023-08-03 DK DK23757194.8T patent/DK4508045T3/da active
- 2023-08-03 HR HRP20251427TT patent/HRP20251427T1/hr unknown
- 2023-08-03 IL IL318739A patent/IL318739A/en unknown
- 2023-08-03 CN CN202380057529.4A patent/CN119866336A/zh active Pending
-
2025
- 2025-01-30 JO JOJO/P/2025/0025A patent/JOP20250025A1/ar unknown
- 2025-01-31 DO DO2025000015A patent/DOP2025000015A/es unknown
- 2025-01-31 CL CL2025000299A patent/CL2025000299A1/es unknown
- 2025-01-31 MX MX2025001312A patent/MX2025001312A/es unknown
- 2025-02-28 CO CONC2025/0002413A patent/CO2025002413A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4508045A2 (en) | 2025-02-19 |
| MX2025001312A (es) | 2025-05-02 |
| AR130114A1 (es) | 2024-11-06 |
| CA3263797A1 (en) | 2024-02-08 |
| RS67422B1 (sr) | 2025-12-31 |
| PE20251236A1 (es) | 2025-04-29 |
| EP4663190A3 (en) | 2026-03-04 |
| MD4508045T2 (ro) | 2026-01-31 |
| JP2025526601A (ja) | 2025-08-15 |
| AU2023317835A1 (en) | 2025-03-20 |
| TW202416955A (zh) | 2024-05-01 |
| PT4508045T (pt) | 2025-10-29 |
| PL4508045T3 (pl) | 2026-03-23 |
| FI4508045T3 (fi) | 2025-11-13 |
| CN119866336A (zh) | 2025-04-22 |
| DOP2025000015A (es) | 2025-04-08 |
| ES3050097T3 (en) | 2025-12-19 |
| EP4663190A2 (en) | 2025-12-17 |
| JOP20250025A1 (ar) | 2025-01-30 |
| WO2024028458A3 (en) | 2024-03-21 |
| IL318739A (en) | 2025-03-01 |
| MA69856B1 (fr) | 2025-10-31 |
| DK4508045T3 (da) | 2025-10-20 |
| EP4508045B1 (en) | 2025-10-01 |
| CO2025002413A2 (es) | 2025-06-16 |
| WO2024028458A2 (en) | 2024-02-08 |
| US20250340531A1 (en) | 2025-11-06 |
| CL2025000299A1 (es) | 2025-08-08 |
| LT4508045T (lt) | 2025-11-25 |
| SI4508045T1 (sl) | 2025-11-28 |
| HRP20251427T1 (hr) | 2025-12-19 |
| KR20250041066A (ko) | 2025-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2025000299A1 (es) | Formas cristalinas y sales de un agonista del receptor muscarínico. | |
| ECSP23044370A (es) | Compuestos farmacéuticos | |
| CO2022015930A2 (es) | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 | |
| CL2022003041A1 (es) | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 | |
| MX2019011693A (es) | Compuestos que inhiben la proteina mcl-1. | |
| MX2020014156A (es) | Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4. | |
| MX379530B (es) | Compuestos agonistas del receptor muscarínico m4. | |
| MX2022001158A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| MX2020006460A (es) | Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar. | |
| MX2020007947A (es) | Inhibidores de erbb/btk. | |
| CR20200464A (es) | Compuestos diólicos de aminopirazina como inhibidores de pi3k-y | |
| AR134657A1 (es) | Compuestos heterocíclicos como agonistas del receptor activador expresado en células mieloides 2 y métodos de uso | |
| CO2022008313A2 (es) | Compuestos químicos | |
| PE20251255A1 (es) | Inhibidores de inflamasoma nlrp3 | |
| MX2019003310A (es) | Inhibidores de dopamina-b-hidroxilasa. | |
| CO2023007617A2 (es) | Prevención y/o tratamiento de enfermedades del snc | |
| CL2022002386A1 (es) | Compuestos de amino pirimidina fusionados | |
| CO2024009091A2 (es) | Compuestos heterociclicos como inhibidores de dyrk1a | |
| PY2221203A (es) | Derivados de ciclobutilo 1,3-sustituidos y sus usos | |
| MX2018008157A (es) | Alfa-amino esteres de derivado de hidroxipropiltiazolidin carboxamida, y formas de sales y polimorfos cristalinos de estos. | |
| CL2019003467A1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| PA8559201A1 (es) | Compuestos azapoliciclicos condensados con arilo | |
| MX2024011425A (es) | Compuestos polimorficos y usos de estos | |
| AR132890A1 (es) | Aminas bicíclicas como inhibidores de cdk2 | |
| AR127622A1 (es) | Compuestos heterocíclicos como agonistas del receptor activador expresado en células mieloides 2 y métodos de uso |